Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

Merck Research Laboratories, Rahway, NJ, USA.
The American Journal of Cardiology (Impact Factor: 3.43). 04/2008; 101(5):625-30. DOI: 10.1016/j.amjcard.2007.10.023
Source: PubMed

ABSTRACT Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2), which leads to poor patient compliance and suboptimal dosing. This phase II dose-ranging study was designed to assess whether the prostaglandin D(2) receptor 1 antagonist laropiprant (LRPT; MK-0524) would (1) reduce extended-release niacin (ERN)-induced flushing in dyslipidemic patients and (2) support a novel accelerated ERN dosing paradigm: initiating ERN at 1 g and advancing rapidly to 2 g. In part A of the study, 154 dyslipidemic patients were randomized to LRPT 150 mg/day or placebo in a 9-week, 2-period crossover study. Patients who completed part A (n = 122) entered part B (after a 2-week washout), together with additional patients who entered part B directly (n = 290). Part B patients were randomized to placebo, ERN 1 g (Niaspan, no previous titration), or ERN 1 g coadministered with LRPT 18.75, 37.5, 75, or 150 mg for 4 weeks, with doubling of the respective doses for the remaining 4 weeks. Patients treated with LRPT plus ERN experienced significantly less ERN-induced flushing than those treated with ERN alone during the initiation of treatment (ERN 1 g, week 1) and the maintenance treatment (ERN 1 to 2 g, weeks 2 to 8). All doses of LRPT were maximally effective in inhibiting niacin-induced flushing. LRPT did not alter the beneficial lipid effects of ERN. LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Präventive Maßnahmen haben einen relevanten Anteil am beobachteten Rückgang kardiovaskulärer Morbidität und Mortalität. Unveränderter Handlungsbedarf auch in der Prävention ergibt sich aus der Tatsache, dass Herz-Kreislauf-Erkrankungen in Deutschland weiter die häufigste Todesursache (42%) geblieben sind. Der gesunde Lebensstil, unverändert Basis aller Empfehlungen, hat seine Grenze in oft unzureichender Compliance oder im individuellen Fall nicht ausreichender Wirksamkeit. Nach der neuen Metaanalyse der Cholesterol Treatment Trialists lässt sich pro 1mmol (39mg/dl) LDL-Cholesterinsenkung mit Statinen eine Reduktion vaskulärer Ereignisse um 21% erreichen. Ob unsere Versorgung mit Lipidsenkern ausreichend ist oder Defizite im Erreichungsgrad der LDL-Cholesterin-Zielwerte Konsequenzen in der Therapieumsetzung haben sollten, wird diskutiert. Als weitere Grenze der modernen Lipidtherapie wird auf das trotz Statintherapie verbleibende kardiovaskuläre Risko hingewiesen. Mögliche Einflussnahmen sind stärkere oder über LDL-Cholesterin hinausgehende Lipoproteinwirkungen. Entsprechend werden indikationsrelevante Charakteristika zur Verfügung stehender lipidwirksamer Maßnahmen abgehandelt und auf zukünftige Entwicklungen hingewiesen. Prevention is a major contributor to the decline in cardiovascular morbidity and mortality. Cardiovascular diseases still are the leading cause of death (42%) in Germany and indicate unmet preventive needs. Limitations of healthy lifestyle, the basis of many recommendations, include insufficient compliance and efficacy in individual cases. In their latest metaanalysis the Cholesterol Treatment Trialists’ Collaborators showed updated estimates of treatment effects of statins including more or less intensive regimens.The average reduction in major vascular events was 21% per 1.0mmol/l reduction in LDL cholesterol. Appropriateness of receiving lipid modulating treatment in the population will be discussed in the light of controversial recommendations in treatment strategies. Residual risk in statin treated patients may be ameliorated by options beyond LDL-lowering. Suggestions for clinical practice are provided on the background of clinical relevant characteristics of current lipid lowering drugs and future developments are outlined. SchlüsselwörterKardiovaskuläres Risiko–Statine–Nikotinsäure–Fibrate–Anionenaustauscher KeywordsCardiovascular risk–Statins–Nicotinic acid–Fibrates–Resins
    Der Internist 03/2011; 52(3):328-335. DOI:10.1007/s00108-010-2799-7 · 0.27 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: An abstract is unavailable. This article is available as HTML full text and PDF.
    Current Opinion in Lipidology 01/2000; 11(1):91-92. DOI:10.1097/00041433-199712000-00014 · 5.80 Impact Factor